Burkitt Lymphoma
Recent clinical, regulatory, research and industry developments relating to this disease.
Estimating the global burden of Epstein-Barr virus-related cancers.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
- Q2 2027Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
- Q1 2030Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
- Q2 2030A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
Clinical MilestonesViewHide
- 2026-05-29Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative RegimenResults expected Q2 2027
- 2026-05-13Phase 1b/2 Trial of Pidnarulex in MYC Aberrant LymphomaResults expected Q1 2030
- 2026-04-23A Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin LymphomasResults expected Q2 2030
- 2025-11-10Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsResults expected Q3 2026
- 2026-05-29ClinicalHematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative RegimenResults expected Q2 2027
- 2026-05-13ClinicalPhase 1b/2 Trial of Pidnarulex in MYC Aberrant LymphomaResults expected Q1 2030
- 2026-04-23ClinicalA Pilot Study of Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin LymphomasResults expected Q2 2030
- 2025-11-10ClinicalSafety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsResults expected Q3 2026
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Lymphoma, Large B-Cell, Diffuse1
Leading journals3
- American journal of hematology1
- Journal for immunotherapy of cancer1
- Journal of cancer research and clinical oncology1
Leading researchers8
- Alkhinji AA1
- Amador C1
- Bhagavathi SK1
- Bi C1
- Bouska A1
- Burrows SR1
- Chan WC1
- Dave BJ1
Affiliations (unnormalised)6
- All India Institute of Medical Sciences1
- Australian Institute of Tropical Health and Medicine1
- Cedars-Sinai Medical Center and Samuel Oschin Comprehensive Cancer Institute1
- Centre for Molecular Therapeutics1
- Centre for Tropical Bioinformatics and Molecular Biology1
- City of Hope National Medical Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.